drugset / Trial / NCT00160862
NK-1 Antagonism of SLV317 in Humans
RandomizedCrossoverDouble-blindDiagnostic
Summary
The primary objective is to determine the effect of a single oral dose of 250 mg SLV 317 on substance P-induced venodilation in the hand vein of healthy male volunteers as compared to placebo.
Timeline
- Start
- 2003-05
- Primary completion
- —
- Completion
- 2003-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SLV317 | Unknown | 250 mg | Oral |
Indications
No indication recorded.